The hypouricemic effect of o,p'-DDD.
o,p'-DDD, administered by mouth in doses of 1 to 7 grams daily for 5 to 42 days, was found to lower serum uric acid concentration in each of eight normouricemic patients (one with Cushing's disease and seven with metastatic cancer). The decrease ranged from 21 to 53% (average 39%) and the maximum effect was apparent in five to ten days. Urinary uric acid excretion showed no change, indicating that uric acid production was unaffected and that the hypouricemic effect resulted from an increase in the renal clearance of uric acid. The present findings introduce a new type of chemical compound to the group of known hypouricemic agents.
D000293:Adolescent; D000368:Aged; D003480:Cushing Syndrome / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D014527:Uric Acid / Q000097:blood* / Q000378:metabolism
D014527:Uric Acid; D008939:Mitotane